Effect of posterior vitreous detachment on aqueous humor level of vascular endothelial growth factor in exudative age-related macular degeneration patients.

Abstract

BACKGROUND:

To investigate the association of posterior vitreous detachment (PVD) with aqueous levels of vascular endothelial growth factor (VEGF) in eyes with exudative age-related macular degeneration (AMD).

METHODS:

This is a prospective comparative study. Subjects are 33 eyes with exudative AMD. PVD was examined by B-mode ultrasonography and the subjects were divided into a complete PVD group (PVD group) or a group with partial or no PVD (without PVD group). At the beginning of intravitreal injection of ranibizumab, aqueous humor was collected and the concentration of VEGF was measured using ELISA. The concentration was compared between the two groups.

RESULTS:

Complete PVD was observed in 13 (39 %) eyes. The mean concentration of VEGF was 58 pg/ml in the PVD group and 91 pg/ml in the without PVD group. Multiple regression analysis revealed that the concentration of VEGF was significantly lower in the eyes with PVD than in those without PVD independent of age and sex (P = 0.02).

CONCLUSIONS:

Complete PVD is related to the lower concentration of aqueous VEDF in AMD eyes.

• Authors: Yoko Nomura, Hidenori Takahashi, Xue Tan, Yujiro Fujino, Hidetoshi Kawashima, Yasuo Yanagi
• Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol) Vol. 254 Issue 1 Pg. 53-7 (Jan 2016) ISSN: 1435-702X [Electronic] Germany
• PMID: 25863675 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Ranibizumab

Topics

• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (therapeutic use)
• Aqueous Humor (metabolism)
• Enzyme-Linked Immunosorbent Assay
• Exudates and Transudates
• Female
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Prospective Studies
• Ranibizumab (therapeutic use)
• Tomography, Optical Coherence
• Ultrasonography
• Vascular Endothelial Growth Factor A (antagonists & inhibitors, metabolism)
• Visual Acuity (physiology)
• Vitreous Detachment (diagnostic imaging, metabolism)
• Wet Macular Degeneration (drug therapy, metabolism, physiopathology)